Michael Carlos, MD
Cardiovascular Disease · Laurel, MDNPI 1760473110
Payments from drug & device makers
Across 151 payments — averaging $17.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$427
- E.r. Squibb & Sons, L.L.C.$351
- Novartis$270
- Pfizer$248
- AstraZeneca$189
- Novo Nordisk$171
- plus $1K from 22 others
What the payments were for
- Food & beverage$2,666100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 19 | $427 |
| E.r. Squibb & Sons, L.L.C. | 22 | $351 |
| Novartis | 22 | $270 |
| Pfizer | 15 | $248 |
| AstraZeneca | 10 | $189 |
| Novo Nordisk | 8 | $171 |
| Johnson & Johnson | 10 | $158 |
| Boehringer Ingelheim | 8 | $141 |
| Esperion Therapeutics, Inc. | 6 | $114 |
| Alnylam Pharmaceuticals Inc. | 4 | $92 |
| Merck | 5 | $85 |
| Amarin Pharma, Inc. | 3 | $52 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 2 | $46 |
| Sanofi-aventis U.S. LLC | 2 | $43 |
| Medtronic(2 entities) | 2 | $41 |
| Boston Scientific | 1 | $28 |
| Phadia US Inc. | 1 | $22 |
| Vivus LLC | 1 | $21 |
| Bayer | 1 | $20 |
| Heartflow, Inc. | 1 | $20 |
| Braemar Manufacturing, LLC | 1 | $19 |
| GSK | 1 | $16 |
| Lilly USA, LLC | 1 | $16 |
| Scpharmaceuticals Inc. | 1 | $16 |
| Regeneron Healthcare Solutions, Inc. | 1 | $16 |
| Cranial Technologies, Inc | 1 | $15 |
| Lexicon Pharmaceuticals, Inc. | 1 | $14 |
| Currax Pharmaceuticals LLC | 1 | $13 |
How this compares
$2,666 in reported general payments places this provider in the 55th percentile of 507 cardiovascular disease providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 259 | $269,450 |
| OzempicSemaglutide | 144 | $159,514 |
| XareltoRivaroxaban | 89 | $100,436 |
| JardianceEmpagliflozin | 79 | $99,509 |
| FarxigaDapagliflozin Propanediol | 94 | $93,625 |
| EntrestoSacubitril/Valsartan | 66 | $91,981 |
| Repatha SureclickEvolocumab | 59 | $54,606 |
| MounjaroTirzepatide | 22 | $29,770 |
| Atorvastatin Calcium | 564 | $7,109 |
| Rosuvastatin Calcium | 209 | $6,123 |
| Ezetimibe | 143 | $5,297 |
| Valsartan | 131 | $4,060 |
| Metoprolol Succinate | 232 | $3,831 |
| Chlorthalidone | 120 | $3,238 |
| Amlodipine Besylate | 244 | $1,888 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $248 | $269,450259 claims |
| Novo NordiskOzempic | $171 | $159,514144 claims |
| Johnson & JohnsonXarelto | $158 | $100,43689 claims |
| Boehringer IngelheimJardiance | $141 | $99,50979 claims |
| AstraZenecaFarxiga | $189 | $93,62594 claims |
| NovartisEntresto | $270 | $91,98166 claims |
| Lilly USA, LLCMounjaro | $16 | $29,77022 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 507 cardiovascular disease providers in Maryland.
Other cardiovascular disease in Laurel
- Christopher DefilippiBaltimore$9.2M
- Thorsten LeuckerBaltimore$7.1M
- Joao LimaBaltimore$5.6M
- Jeffrey ColeBaltimore$4.8M
- Carlos InceBaltimore$3M
- Paul GurbelBaltimore$2.6M
- Navin KapurBaltimore$1.8M
- Vineet VenugopalLanham$1.5M
- Robert WeissBaltimore$1.4M
- Stephen GottliebBaltimore$1.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.